IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Robert S. Meissner et al

Serial No.

10/551,975

Filed:

October 5, 2005

For: ANDROGEN RECEPTOR MODULATORS AND

METHODS OF USE THEREOF

To Be Assigned

Examiner:

Art Unit:

To Be Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

nela Spalding Date 1-5-06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		
		+		

If this is inconvenient, additional copies will be submitted upon request. 6. In accordance with 37 C.F.R. 1.97, (check one) the attached information is filed within three months of the filing date of the captioned case. the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits. the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114. the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement. Respectfully submitted, By: Patricia A. Shatynski Attorney For Applicant(s) Reg. No. 43,109 MERCK & CO., INC. Patent Dept., RY60-30 P.O. Box 2000 Rahway, N.J. 07065-0907 (732)594-1652 Date: January 5, 2006

Sı	ubstitute for form 1449A/PTO		-	COMPLETE IF KNOWN			
	NFORMATION	DIS	CLOSURE	Application Number	10/551,975		
C	STATEMENT BY APPLICANT			Filing Date	October 5, 2005		
3	IAIEMENI BY	AP	PLICANI	First Named Inventor Robert S. Meissner			
				Group Art Unit	To Be Assigned		
	(use as many sheets as necessary)		Examiner Name	To Be Assigned			
Sheet	1	of	2	Attorney Docket Number	20880P		

			U.S. P	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	US 5,620,986		Witzel et al	04/15/1997
	2	US 5,639,741		Witzel et al	06/17/1997
	3	US 5,494,914		Labrie et al	02/27/1996
	4	US 5,693,809		Durette et al	12/02/1997
	5	US 5,710,275		Bakshi et al	01/20/1998
	6	US 5,583,138		Tuba et al	12/10/1996
	7	US 4,377,584		Rasmusson et al	03/22/1983
	8	US 5,359,071		Durette et al	10/25/1994
	9	US 5,583,228		Tuba et al	12/10/1996
		· .			
		•			

	FOREIGN PATENT DOCUMENTS							
Examiner Cir	Cite		Foreign Patent Document		V	Date of Publication of		
Initials*	No.	Office	e Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
	1	PCT	WO 97/30069		Hoechst Marion Roussel, Inc	08/21/1997		
	2	PCT	WO 95/00531		Richter Gedion Vegyeszeti Gyar Rt	01/05/1995		

	.	
Examiner	Date	
Signature	Considered	
- B	00110100100	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO		COMPLETE IF KNOWN				
	NFORMATION 1	DIS	CLOSURE	Application Number	10/551,975	
				Filing Date	October 5, 2005	_
5	STATEMENT BY APPLICANT			First Named Inventor	Robert S. Meissner	
			,	Group Art Unit	To Be Assigned	
(use as many sheets as necessary)			ecessary)	Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	20880P	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	1	M. Lourdusamy et al., "Synthesis and In Vitro Study of 17 beta-[N-Ureylene-N,N'-disubstituted]-4-methyl-4-aza-5 alpha-Androstan-3-ones as Selective Inhibitors of Type I 5 alpha-Reductase", Bioorganic & Medicinal Chemistry, Vol. 5, pp 305-310, 1997					
	2	X. Li et al., "Synthesis and in Vitro Activity of 17 beta-(N-Alkyl/arylformamido)-and 17 beta-[(N-Alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3", J. Med. Chem, Vol. 38, pp 1158-1173, 1995					
	3	C. Chen et al., "Activity of 17 beta-(N-Alkyl/arylformamido) and 17 beta-[N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5a-androstan-3-ones as 5 alpha-Reductase Inhibitors in the Hamster Flank Organ and Ear", The Journal of Investigative Dermatology, Vol. 111, pp 273-278, 1998					
	4	G.H. Rasmusson et al., "Azasteroids: Structure-Activity Relationships for Inhibition of 5 alpha-Reductase and of Androgen Receptor Binding", J. Med. Chem., Vol. 29, pp 2298-2315, 1986					
	5	G.H. Rasmusson et al., "Azasteroids as Inhibitos of Rat Prostatic 5 alpha-Reductase", J. Med. Chem, Vol. 27, pp 1690-1701, 1984					
	6	W.E. Solomons et al., "Synthesis and Antimicrobial Properties of 17 beta-Amino-4-aza-5 alpha-androstane and Derivatives", Journal of Pharmaceutical Sciences, Vol 63, pp 19-23, 1974					

Examiner		Date	
Signature		Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.